+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evidence for lymphatic destruction in prostate carcinoma assessed with the novel lymphatic marker LYVE-1



Evidence for lymphatic destruction in prostate carcinoma assessed with the novel lymphatic marker LYVE-1



European Urology Suppl.s 2(1): 162




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034888871

Download citation: RISBibTeXText

DOI: 10.1016/s1569-9056(03)80640-1


Related references

Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). Journal of Urology 172(1): 103-107, 2004

A novel marker for lymphatic vessels - evidence for lymphatic destruction in prostate cancer. Journal of Urology 169(4 Suppl.): 154, 2003

Lymph vessel destruction in prostatic cancer LYVE-1 as novel lymphatic marker. Pathology Research & Practice 199(4): 201, 2003

Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. Apmis 112(7-8): 526-538, 2004

Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. Blood 121(7): 1229-1237, 2013

Locally advanced prostate carcinoma (T2b-T4 N0) without and with clinical evidence of local progression (Tx N+) with lymphatic metastasis. Is radiotherapy for pelvic lymphatic metastasis indicated or not?. Strahlentherapie und Onkologie 174(5): 231-236, 1998

Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Molecular and Cellular Biology 27(2): 595-604, 2007

Characterization of cells expressing lymphatic marker LYVE-1 in macaque large intestine during simian immunodeficiency virus infection identifies a large population of nonvascular LYVE-1(+)/DC-SIGN(+) cells. Lymphatic Research and Biology 11(1): 26-34, 2013

Lymphatic vascular endothelial hyaluronan receptor (LYVE)-1- and CCL21-positive lymphatic compartments in the diabetic thymus. Anatomical Science International 81(4): 201-209, 2006

Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression. RadioTherapy and Oncology 77(2): 172-175, 2005

Expression and quantitation of lymphatic endothelial marker, LYVE-1, mRNA in breast cancer. Breast Cancer Research & Treatment 69(3): 265, 2001

The expression of the lymphatic endothelial cell marker LYVE-1 in benign and malignant vascular tumours. Journal of Pathology 201(Suppl.): 57A, 2003

Expression of the hyaluronan receptor LYVE-1 is not restricted to the lymphatic vasculature; LYVE-1 is also expressed on embryonic blood vessels. Developmental Dynamics 237(7): 1901-1909, 2008

Immunohistochemical examination on the distribution of cells expressed lymphatic endothelial marker podoplanin and LYVE-1 in the mouse tongue tissue. Acta Histochemica et Cytochemica 43(2): 61-68, 2010

Lymphatic endothelial cancerization in papillary thyroid carcinoma: hidden evidence of lymphatic invasion. Pathology International 65(5): 220-230, 2015